| Catalog No. | VK515016 |
|---|
| Description | Diridavumab, the alternative name, CR6261, is a human monoclonal antibody directed against influenza A hemagglutinin. The CR6261 antibody was first discovered by the Scripps Institute and Crucell, a Dutch biopharmaceutical company, and later developed by Janssen Pharmaceutical Companies of Johnson & Johnson under the trade name diridavumab. Cr6261 is under investigation in clinical trial NCT02016066 (A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of Diridavumab in Japanese Healthy Participants). |
|---|
| Species reactivity | Influenza A virus |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Host species | Human |
|---|
| Isotype | IgG1, lambda |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | HA/Hemagglutinin |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G purified from cell culture supernatant. |
|---|
| Accession | P03455 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| Alternate Names | CR-6261, CR6261, 1393659-46-5 |
|---|
| Background | HY-P990944 is an influenza A virus hemagglutinin HA-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).
• A soluble domain of the membrane-anchoring chain of influenza virus hemagglutinin (HA2) folds in Escherichia coli into the low-pH-induced conformation., PMID:8618870
• Recognition of influenza virus hemagglutinin by subtype-specific and cross-reactive proliferative T cells: contribution of HA1 and HA2 polypeptide chains., PMID:3871116
• Molecular mechanisms of the influenza fusion peptide: insights from experimental and simulation studies., PMID:34710289
• Anti-hemagglutinin monomeric nanobody provides prophylactic immunity against H1 subtype influenza A viruses., PMID:38985719
• Reversible structural changes in the influenza hemagglutinin precursor at membrane fusion pH., PMID:35939703
• A monoclonal antibody specific to the HA2 glycoprotein of influenza A virus hemagglutinin that inhibits its fusion activity reduces replication of the virus., PMID:15068378
• Structural studies on membrane-embedded influenza hemagglutinin and its fragments., PMID:9300499
• Charged N-terminus of Influenza Fusion Peptide Facilitates Membrane Fusion., PMID:29443945
• Is virulence of H5N2 influenza viruses in chickens associated with loss of carbohydrate from the hemagglutinin?, PMID:6516214
• Molecular composition of the 16S toxin produced by a Clostridium botulinum type D strain, 1873., PMID:9802560
|
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
